The first study of note is an attempt by Liu and colleagues [250] who noted KRAS-G12D mutation responsible for suppressing the PD-L1 targeted therapy and CXCL10/CXCL11 (chemokines) secretion, together suppressing the CD8+ tumor infiltrating lymphocytes (TILs). Here, CXCL11 is linked to neoplasm.